Janssen's Invega Sustenna Will Become Decision Resources' Proprietary Clinical Gold Standard in 2013 for the Treatment of Schizo

A Drug's Impact on Global Symptoms and Its Effect on Positive Symptoms Are the Attributes that Most Influence Surveyed Psychiatrists' Prescribing Decisions in Schizophrenia, According to a New Report from Decision Resources

WALTHAM, Mass., April 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Janssen's Invega Sustenna earns Decision Resources' proprietary clinical gold standard status for the treatment of schizophrenia in 2013. Invega Sustenna has competitive advantages in safety, tolerability and delivery over current and emerging therapies.

"Invega Sustenna, which launched in the second half of 2009, was the first-to-market atypical antipsychotic injection to be dosed once a month. Its dosing frequency gives it a competitive edge in patient compliance compared with the current gold standard, Janssen's Risperdal Consta, which is dosed every two weeks," stated Decision Resources Analyst Natalie Taylor, Ph.D. "Additionally, the Invega Sustenna injection is conveniently packaged as a prefilled syringe that doesn't require reconstitution or refrigeration, unlike other available and emerging atypical antipsychotic depot formulations."

The new report entitled Schizophrenia: Emerging Atypical Depot Formulations Must Meet Psychiatrists' High Expectations to Be Successful in a Generically Threatened Market also finds that a drug's impact on global symptoms and its effect on positive symptoms are the attributes that most influence surveyed psychiatrists' prescribing decisions in schizophrenia. However, clinical data and the opinions of interviewed thought leaders indicate that current and emerging therapies have no advantage over sales-leading Eli Lilly's Zyprexa on these attributes. Instead, the commercial success of emerging therapies (both oral and depot formulations) is expected to be dependent upon safety and delivery advantages.

About the Report

Schizophrenia: Emerging Atypical Depot Formulations Must Meet Psychiatrists' High Expectations to Be Successful in a Generically Threatened Market is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development. 

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources, Inc.

Christopher Comfort


[email protected]

SOURCE Decision Resources, Inc.